Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TSI Corporation

This article was originally published in The Gray Sheet

Executive Summary

Plans to reduce staff by approximately 10%. The cuts primarily will affect two of the Worcester, Massachusetts-based company's seven divisions: the Argus preclinical in vivo toxicology lab division and the Health and Sciences Research Inc. clinical testing facility. Administrative staff throughout the firm will also be affected. The reductions respond to an expected 15% revenue decline from the previous quarter, which TSI attributes to "a slowdown in the product development activity in its principal market, the biopharmaceutical industry." The cost-cutting measures also represent the company's consolidation of "certain functions" following seven 1991 and 1992 acquisitions.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts